240 related articles for article (PubMed ID: 30199322)
1. MHC-associated peptide proteomics enabling highly sensitive detection of immunogenic sequences for the development of therapeutic antibodies with low immunogenicity.
Sekiguchi N; Kubo C; Takahashi A; Muraoka K; Takeiri A; Ito S; Yano M; Mimoto F; Maeda A; Iwayanagi Y; Wakabayashi T; Takata S; Murao N; Chiba S; Ishigai M
MAbs; 2018; 10(8):1168-1181. PubMed ID: 30199322
[TBL] [Abstract][Full Text] [Related]
2. Development of a semi-automated MHC-associated peptide proteomics (MAPPs) method using streptavidin bead-based immunoaffinity capture and nano LC-MS/MS to support immunogenicity risk assessment in drug development.
Lee MV; Saad OM; Wong S; LaMar J; Kamen L; Ordonia B; Melendez R; Hassanzadeh A; Chung S; Kaur S
Front Immunol; 2023; 14():1295285. PubMed ID: 38022649
[TBL] [Abstract][Full Text] [Related]
3. Immunopeptidomic Data Integration to Artificial Neural Networks Enhances Protein-Drug Immunogenicity Prediction.
Barra C; Ackaert C; Reynisson B; Schockaert J; Jessen LE; Watson M; Jang A; Comtois-Marotte S; Goulet JP; Pattijn S; Paramithiotis E; Nielsen M
Front Immunol; 2020; 11():1304. PubMed ID: 32655572
[TBL] [Abstract][Full Text] [Related]
4. MAPPs for the identification of immunogenic hotspots of biotherapeutics; an overview of the technology and its application to the biopharmaceutical arena.
Quarmby V; Phung QT; Lill JR
Expert Rev Proteomics; 2018 Sep; 15(9):733-748. PubMed ID: 30198337
[TBL] [Abstract][Full Text] [Related]
5. Applying MAPPs Assays to Assess Drug Immunogenicity.
Karle AC
Front Immunol; 2020; 11():698. PubMed ID: 32373128
[TBL] [Abstract][Full Text] [Related]
6. Assessing MAPPs assay as a tool to predict the immunogenicity potential of protein therapeutics.
Di Ianni A; Fraone T; Balestra P; Cowan K; Riccardi Sirtori F; Barbero L
Life Sci Alliance; 2024 Jan; 7(1):. PubMed ID: 37833075
[TBL] [Abstract][Full Text] [Related]
7. Enabling Routine MHC-II-Associated Peptide Proteomics for Risk Assessment of Drug-Induced Immunogenicity.
Steiner G; Marban-Doran C; Langer J; Pimenova T; Duran-Pacheco G; Sauter D; Langenkamp A; Solier C; Singer T; Bray-French K; Ducret A
J Proteome Res; 2020 Sep; 19(9):3792-3806. PubMed ID: 32786679
[TBL] [Abstract][Full Text] [Related]
8. The MHC Associated Peptide Proteomics assay is a useful tool for the non-clinical assessment of immunogenicity.
Jankowski W; Kidchob C; Bunce C; Cloake E; Resende R; Sauna ZE
Front Immunol; 2023; 14():1271120. PubMed ID: 37915568
[TBL] [Abstract][Full Text] [Related]
9. Expanding the MAPPs Assay to Accommodate MHC-II Pan Receptors for Improved Predictability of Potential T Cell Epitopes.
Hartman K; Steiner G; Siegel M; Looney CM; Hickling TP; Bray-French K; Springer S; Marban-Doran C; Ducret A
Biology (Basel); 2023 Sep; 12(9):. PubMed ID: 37759665
[TBL] [Abstract][Full Text] [Related]
10. Systematically benchmarking peptide-MHC binding predictors: From synthetic to naturally processed epitopes.
Zhao W; Sher X
PLoS Comput Biol; 2018 Nov; 14(11):e1006457. PubMed ID: 30408041
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and tolerogenicity of self-major histocompatibility complex peptides.
Benichou G; Takizawa PA; Ho PT; Killion CC; Olson CA; McMillan M; Sercarz EE
J Exp Med; 1990 Nov; 172(5):1341-6. PubMed ID: 1700053
[TBL] [Abstract][Full Text] [Related]
12. Sequence conservation analysis and in silico human leukocyte antigen-peptide binding predictions for the Mtb72F and M72 tuberculosis candidate vaccine antigens.
Mortier MC; Jongert E; Mettens P; Ruelle JL
BMC Immunol; 2015 Oct; 16():63. PubMed ID: 26493839
[TBL] [Abstract][Full Text] [Related]
13. Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity.
Karle A; Spindeldreher S; Kolbinger F
MAbs; 2016; 8(3):536-50. PubMed ID: 26817498
[TBL] [Abstract][Full Text] [Related]
14. MHC class II loading of high or low affinity peptides directed by Ii/peptide fusion constructs: implications for T cell activation.
Gregers TF; Fleckenstein B; Vartdal F; Roepstorff P; Bakke O; Sandlie I
Int Immunol; 2003 Nov; 15(11):1291-9. PubMed ID: 14565927
[TBL] [Abstract][Full Text] [Related]
15. Improved prediction of HLA antigen presentation hotspots: Applications for immunogenicity risk assessment of therapeutic proteins.
Attermann AS; Barra C; Reynisson B; Schultz HS; Leurs U; Lamberth K; Nielsen M
Immunology; 2021 Feb; 162(2):208-219. PubMed ID: 33010039
[TBL] [Abstract][Full Text] [Related]
16. Characterizing immunodominant and protective influenza hemagglutinin epitopes by functional activity and relative binding to major histocompatibility complex class II sites.
Rajnavölgyi E; Horváth A; Gogolák P; Tóth GK; Fazekas G; Fridkin M; Pecht I
Eur J Immunol; 1997 Dec; 27(12):3105-14. PubMed ID: 9464794
[TBL] [Abstract][Full Text] [Related]
17. Identification of MHC-Bound Peptides from Dendritic Cells Infected with Salmonella enterica Strain SL1344: Implications for a Nontyphoidal Salmonella Vaccine.
Karunakaran KP; Yu H; Jiang X; Chan Q; Goldberg MF; Jenkins MK; Foster LJ; Brunham RC
J Proteome Res; 2017 Jan; 16(1):298-306. PubMed ID: 27802388
[TBL] [Abstract][Full Text] [Related]
18. Predicting Hemagglutinin MHC-II Ligand Analogues in Anti-TNFα Biologics: Implications for Immunogenicity of Pharmaceutical Proteins.
Andrick BJ; Schwab AI; Cauley B; O'Donnell LA; Meng WS
PLoS One; 2015; 10(8):e0135451. PubMed ID: 26270649
[TBL] [Abstract][Full Text] [Related]
19. The majority of immunogenic epitopes generate CD4+ T cells that are dependent on MHC class II-bound peptide-flanking residues.
Arnold PY; La Gruta NL; Miller T; Vignali KM; Adams PS; Woodland DL; Vignali DA
J Immunol; 2002 Jul; 169(2):739-49. PubMed ID: 12097376
[TBL] [Abstract][Full Text] [Related]
20. Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity.
Feltkamp MC; Vierboom MP; Kast WM; Melief CJ
Mol Immunol; 1994 Dec; 31(18):1391-401. PubMed ID: 7823965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
